PMID- 35901098
OWN - NLM
STAT- MEDLINE
DCOM- 20220801
LR  - 20220815
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 17
IP  - 7
DP  - 2022
TI  - Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage 
      chemotherapy following immune checkpoint inhibitors for recurrent or metastatic 
      head and neck squamous cell carcinoma: A multicenter clinical study.
PG  - e0271907
LID - 10.1371/journal.pone.0271907 [doi]
LID - e0271907
AB  - OBJECTIVES: The benefit of sequential therapy after immune checkpoint inhibitor 
      (ICI) treatment for recurrent or metastatic head and neck squamous cell carcinoma 
      (R/M HNSCC) has been recently reported. Furthermore, there is a growing interest 
      in the impact of cetuximab (Cmab)-containing salvage chemotherapy (SCT) and the 
      therapeutic efficacy and adverse events (AEs) of Cmab administration prior to ICI 
      administration. MATERIALS AND METHODS: We retrospectively reviewed the medical 
      records of 52 patients with R/M HNSCC treated with SCT (weekly paclitaxel [PTX], 
      n = 7, or weekly PTX and Cmab [PC], n = 45). RESULTS: The objective response rate 
      (ORR) and a disease control rate (DCR) was 53.3% and 91.1% in the PC group and 
      42.9% and 57.1% in the PTX group, respectively. There was a significant 
      difference in the DCR between the PC and PTX groups (p = 0.0143). The overall 
      survival (OS) and progression-free survival were significantly better in the PC 
      group than in the PTX group. On the other hand, the incidence of drug-induced 
      interstitial pneumonia (DI-IP) in R/M HNSCC patients who received SCT was 21.2%. 
      Patients in the PC group were divided according to whether they received Cmab 
      (Group A) or did not receive Cmab (Group B) as palliative therapy prior to ICIs. 
      Group B had a significantly better OS than Group A. Furthermore, our findings 
      suggest that the incidence rate of DI-IP during SCT might be higher in Group B. 
      CONCLUSION: Although PC following ICIs shows dramatic efficacy, careful 
      monitoring of AEs, including DI-IP, is recommended.
FAU - Wakasaki, Takahiro
AU  - Wakasaki T
AUID- ORCID: 0000-0001-7736-9162
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
AD  - Department of Head and Neck Surgery, National Hospital Organization, Kyushu 
      Cancer Center, Fukuoka, Japan.
FAU - Manako, Tomomi
AU  - Manako T
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Yasumatsu, Ryuji
AU  - Yasumatsu R
AUID- ORCID: 0000-0002-5765-9418
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
AD  - Department of Otorhinolaryngology-Head and Neck Surgery, Faculty of Medicine, 
      Kindai University, Osaka, Japan.
FAU - Hara, Hirotaka
AU  - Hara H
AD  - Department of Head and Neck Surgery, National Hospital Organization, Kyushu 
      Cancer Center, Fukuoka, Japan.
FAU - Toh, Satoshi
AU  - Toh S
AD  - Department of Head and Neck Surgery, National Hospital Organization, Kyushu 
      Cancer Center, Fukuoka, Japan.
FAU - Masuda, Muneyuki
AU  - Masuda M
AD  - Department of Head and Neck Surgery, National Hospital Organization, Kyushu 
      Cancer Center, Fukuoka, Japan.
FAU - Yamauchi, Moriyasu
AU  - Yamauchi M
AUID- ORCID: 0000-0002-7719-4187
AD  - Department of Otolaryngology, Head and Neck Surgery, Saga University Hospital, 
      Saga, Japan.
FAU - Kuratomi, Yuichiro
AU  - Kuratomi Y
AD  - Department of Otolaryngology, Head and Neck Surgery, Saga University Hospital, 
      Saga, Japan.
FAU - Nishimura, Emi
AU  - Nishimura E
AD  - Department of Otorhinolaryngology, Kitakyushu Municipal Medical Center, 
      Kitakyushu, Japan.
FAU - Takeuchi, Toranoshin
AU  - Takeuchi T
AD  - Department of Otorhinolaryngology, Kitakyushu Municipal Medical Center, 
      Kitakyushu, Japan.
FAU - Matsuo, Mioko
AU  - Matsuo M
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Jiromaru, Rina
AU  - Jiromaru R
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Hashimoto, Kazuki
AU  - Hashimoto K
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Komune, Noritaka
AU  - Komune N
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Nakagawa, Takashi
AU  - Nakagawa T
AD  - Department of Otorhinolaryngology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20220728
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - P88XT4IS4D (Paclitaxel)
RN  - PQX0D8J21J (Cetuximab)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - *Cetuximab/adverse effects
MH  - *Head and Neck Neoplasms/drug therapy/etiology
MH  - Humans
MH  - *Immune Checkpoint Inhibitors
MH  - Neoplasm Recurrence, Local/pathology
MH  - *Paclitaxel/adverse effects
MH  - Retrospective Studies
MH  - Squamous Cell Carcinoma of Head and Neck/drug therapy/etiology
PMC - PMC9333293
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/07/29 06:00
MHDA- 2022/08/02 06:00
PMCR- 2022/07/28
CRDT- 2022/07/28 13:54
PHST- 2021/11/15 00:00 [received]
PHST- 2022/07/10 00:00 [accepted]
PHST- 2022/07/28 13:54 [entrez]
PHST- 2022/07/29 06:00 [pubmed]
PHST- 2022/08/02 06:00 [medline]
PHST- 2022/07/28 00:00 [pmc-release]
AID - PONE-D-21-36204 [pii]
AID - 10.1371/journal.pone.0271907 [doi]
PST - epublish
SO  - PLoS One. 2022 Jul 28;17(7):e0271907. doi: 10.1371/journal.pone.0271907. 
      eCollection 2022.